Lung Cancer Clinical Trial

Screening Study for Participants With Malignant Tumors

Summary

The study objective is to determine the biomarker status of a participant's tumor tissue and use that status to determine eligibility for a linked Roche clinical trial.

View Eligibility Criteria

Eligibility Criteria

General Inclusion Criteria:

Confirmed availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen meeting criteria defined in the protocol
Considered by principal investigator (PI) to be a candidate for a linked clinical trial with an investigational medicinal product, and that the participant has the awareness and willingness to participate in said trial

Inclusion Criteria for Participants with Stage III NSCLC

Locally advanced, unresectable Stage III NSCLC of either squamous or non-squamous histology based on 8th edition of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) cancer staging system
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

General Exclusion Criteria:

History of malignancy other than NSCLC within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death
Any condition that may affect the interpretation of study results
Significant liver or cardiovascular disease
Prior allogenic stem-cell or solid-organ transplantation

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

15000

Study ID:

NCT05419375

Recruitment Status:

Recruiting

Sponsor:

Hoffmann-La Roche

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 19 Locations for this study

See Locations Near You

Arizona Oncology Associates, PC - HOPE
Tucson Arizona, 85704, United States
Rocky Mountain Cancer Centers-Penrose Pavillion
Longmont Colorado, 80504, United States
Thompson Cancer Survival Center
Knoxville Tennessee, 37916, United States
Texas Oncology, P.A.
Austin Texas, 78745, United States
Texas Oncology, P.A.
San Antonio Texas, 78229, United States
Texas Oncology, P.A. - Tyler; Tyler Cancer Center
Tyler Texas, 75702, United States
Oncology & Hematology Associates of Southwest Virginia, Inc
Blacksburg Virginia, 24060, United States
Northwest Cancer Specialists
Vancouver Washington, 98686, United States
Clinica CIMCA
San José , 10103, Costa Rica
ICIMED Instituto de Investigación en Ciencias Médicas
San José , 10108, Costa Rica
Queen Mary Hospital; Dept. of Clinical Oncology
Hong Kong , , Hong Kong
National Hospital Organization Himeji Medical Center
Hyogo , 670-8, Japan
Sendai Kousei Hospital
Miyagi , 980-0, Japan
Nara Medical University Hospital
Nara , 634-8, Japan
Okayama University Hospital
Okayama , 700-8, Japan
Kurashiki Central Hospital
Okayama , 710-8, Japan
Tottori University Hospital
Tottori , 683-8, Japan
Kyungpook National University Chilgok Hospital
Daegu , 41404, Korea, Republic of
Seoul National University Bundang Hospital
Seongnam-si , 13605, Korea, Republic of
Korea University Guro Hospital
Seoul , 08308, Korea, Republic of

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

15000

Study ID:

NCT05419375

Recruitment Status:

Recruiting

Sponsor:


Hoffmann-La Roche

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.